Panelists discuss how head and neck cancer treatment has evolved to include combined therapeutic approaches using surgery, radiation, chemotherapy with cisplatin, and newer immunotherapies, such as ...

Late-breaking abstracts at ESMO are generally reserved for high-quality, new research findings from randomized Phase 2 or Phase 3 trials with implications for clinical practice or understanding of ...

Glenn Hanna, MD, a head and neck cancer specialist at Dana-Farber Cancer Institute, provides a comprehensive overview of ...

The KOL event will be held at the Berlin Germany Marriott starting at 10AM CEST on Sunday October 19 th. The event will feature insights from leading HNSCC experts: Cesar Augusto Perez Batista, MD - ...

In a study published in the Journal of the National Cancer Institute, Mass General Brigham researchers show that a novel ...

The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.

Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Heidi Berghäll, EQA Solutions Manager, R&D of Labquality, commented, "It is important that both pathology and molecular tests are validated via a proper EQA scheme to monitor ongoing performance.